Neuromuscular ultrasound for taxane peripheral neuropathy in breast cancer. Issue 5 (24th February 2020)

• Record Type: Journal Article
• Authors: Lycan, Thomas W.; Hsu, Fang‐Chi; Ahn, Christine S.; Thomas, Alexandra; Walker, Francis O.; Sangueza, Omar P.; Shiozawa, Yusuke; Park, Sun Hee; Peters, Christopher M.; Romero‐Sandoval, Edgar Alfonso; Melin, Susan A.; Sorscher, Steven; Ansley, Katherine; Lesser, Glenn J.; Cartwright, Michael S.; Strowd, Roy E.
• Is Part Of: Muscle & nerve. Volume 61:Issue 5(2020)
• Page Start: 587
• Page End: 594
• Publication Date: 2020-02-24
• Subjects: breast cancer -- chemotherapy -- neuropathy -- taxane -- ultrasound; Neuromuscular diseases -- Periodicals; Muscles -- Periodicals; Nerves -- Periodicals; 616.74
• DOI: 10.1002/mus.26833
• Languages: English
• ISSNs: 0148-639X

Abstract

Abstract: Background: Our study aim was to evaluate neuromuscular ultrasound (NMUS) for the assessment of taxane chemotherapy‐induced peripheral neuropathy (CIPN), the dose‐limiting toxicity of this agent. Methods: This cross‐sectional study of breast cancer patients with taxane CIPN measured nerve cross‐sectional area (CSA) by NMUS and compared with healthy historical controls. Correlations were determined between CSA and symptom scale, nerve conduction studies, and intraepidermal nerve fiber density (IENFD). Results: A total of 20 participants reported moderate CIPN symptoms at a median of 3.8 months following the last taxane dose. Sural nerve CSA was 1.2 mm 2 smaller than healthy controls ( P ≤ .01). Older age and time since taxane were associated with smaller sural nerve CSA. For each 1 mm 2 decrease in sural nerve CSA, distal IENFD decreased by 2.1 nerve/mm (R 2 0.30; P = .04). Conclusions: These data support a sensory predominant taxane neuropathy or neuronopathy and warrant future research on longitudinal NMUS assessment of CIPN.